These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 35869032)

  • 1. Nanomedicine Strategies for Heating "Cold" Ovarian Cancer (OC): Next Evolution in Immunotherapy of OC.
    Yang Y; Zhao T; Chen Q; Li Y; Xiao Z; Xiang Y; Wang B; Qiu Y; Tu S; Jiang Y; Nan Y; Huang Q; Ai K
    Adv Sci (Weinh); 2022 Oct; 9(28):e2202797. PubMed ID: 35869032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of TIM-3 in ovarian cancer: the forsaken cop or a new noble.
    Chang X; Miao J
    Front Immunol; 2024; 15():1407403. PubMed ID: 39206199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combining Nanomedicine and Immunotherapy.
    Shi Y; Lammers T
    Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging Sonodynamic Therapy-Based Nanomedicines for Cancer Immunotherapy.
    Yang Y; Huang J; Liu M; Qiu Y; Chen Q; Zhao T; Xiao Z; Yang Y; Jiang Y; Huang Q; Ai K
    Adv Sci (Weinh); 2023 Jan; 10(2):e2204365. PubMed ID: 36437106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-Targeted Nanomedicine for Immunotherapy.
    Cabral H; Kinoh H; Kataoka K
    Acc Chem Res; 2020 Dec; 53(12):2765-2776. PubMed ID: 33161717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carrier-Free Nanomedicine for Cancer Immunotherapy.
    Fu Y; Bian X; Li P; Huang Y; Li C
    J Biomed Nanotechnol; 2022 Apr; 18(4):939-956. PubMed ID: 35854464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy and the ovarian cancer microenvironment: Exploring potential strategies for enhanced treatment efficacy.
    Wang ZB; Zhang X; Fang C; Liu XT; Liao QJ; Wu N; Wang J
    Immunology; 2024 Sep; 173(1):14-32. PubMed ID: 38618976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-Microenvironment-Responsive Nanomedicine for Enhanced Cancer Immunotherapy.
    Peng S; Xiao F; Chen M; Gao H
    Adv Sci (Weinh); 2022 Jan; 9(1):e2103836. PubMed ID: 34796689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulating the tumor immune microenvironment with nanoparticles: A sword for improving the efficiency of ovarian cancer immunotherapy.
    Xu T; Liu Z; Huang L; Jing J; Liu X
    Front Immunol; 2022; 13():1057850. PubMed ID: 36532066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and validation of pyroptosis-related gene landscape in prognosis and immunotherapy of ovarian cancer.
    Gao L; Ying F; Cai J; Peng M; Xiao M; Sun S; Zeng Y; Xiong Z; Cai L; Gao R; Wang Z
    J Ovarian Res; 2023 Jan; 16(1):27. PubMed ID: 36707884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanomedicines for reversing immunosuppressive microenvironment of hepatocellular carcinoma.
    Pan X; Ni S; Hu K
    Biomaterials; 2024 Apr; 306():122481. PubMed ID: 38286109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancing Cancer Immunotherapeutic Efficacy with Sonotheranostic Strategies.
    Zafar A; Hasan M; Tariq T; Dai Z
    Bioconjug Chem; 2022 Jun; 33(6):1011-1034. PubMed ID: 34793138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Engineered nanomedicines for augmenting the efficacy of colorectal cancer immunotherapy.
    Abdelgalil RM; Elmorshedy YM; Elkhodairy KA; Teleb M; Bekhit AA; Khattab SN; Elzoghby AO
    Nanomedicine (Lond); 2022 Sep; 17(22):1721-1745. PubMed ID: 36621872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Remodeling tumor microenvironment with nanomedicines.
    Martin JD; Miyazaki T; Cabral H
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2021 Nov; 13(6):e1730. PubMed ID: 34124849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterogeneity of immune microenvironment in ovarian cancer and its clinical significance: a retrospective study.
    Gao Y; Chen L; Cai G; Xiong X; Wu Y; Ma D; Li SC; Gao Q
    Oncoimmunology; 2020; 9(1):1760067. PubMed ID: 32391193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ovarian cancer treatment and natural killer cell-based immunotherapy.
    Fan Z; Han D; Fan X; Zhao L
    Front Immunol; 2023; 14():1308143. PubMed ID: 38187402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of functional nanomedicines for tumor associated macrophages-focused cancer immunotherapy.
    Wei X; Wang J; Liang M; Song M
    Theranostics; 2022; 12(18):7821-7852. PubMed ID: 36451865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multi-functional nanomedicines for combinational cancer immunotherapy that transform cold tumors to hot tumors.
    Cho H; Kim K
    Expert Opin Drug Deliv; 2024 Apr; 21(4):627-638. PubMed ID: 38682272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges.
    Martin JD; Cabral H; Stylianopoulos T; Jain RK
    Nat Rev Clin Oncol; 2020 Apr; 17(4):251-266. PubMed ID: 32034288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Normalizing tumor microenvironment with nanomedicine and metronomic therapy to improve immunotherapy.
    Mpekris F; Voutouri C; Panagi M; Baish JW; Jain RK; Stylianopoulos T
    J Control Release; 2022 May; 345():190-199. PubMed ID: 35271911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.